Annual Meeting 2014 – Miller – Bevacizumab in the adjuvant treatment of HER2 negative breast cancer

For more free video updates go to www.oncologyeducation.com
Incorporation of Bv into anthracycline and taxane containing adjuvant therapy does not improve IDFS or OS in pts with high risk HER2- breast cancer. Bv did increase AEs but no unexpected AEs were encountered. Longer duration therapy is unlikely to be feasible given the high rate of early discontinuation due to all causes.